Phase 2 Chronic Kidney Disease Trial, Recruiting NCT07271186 Sponsor: Regeneron Pharmaceuticals Condition: Chronic Kidney Disease
Back to Chronic Kidney Disease

Phase 2 Chronic Kidney Disease Trial, Recruiting

NCT07271186
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with type 2 diabetes and are currently receiving medication or making lifestyle changes to manage their blood sugar levels.
  • People whose HbA1c (a blood test that shows average blood sugar levels over the past few months) is between 6.5% and 10% at the time of screening.
  • People whose kidneys are working at a reduced but not severely low level, as measured by a specific kidney function test called eGFR, with a result between 30 and 90 at screening (confirm with trial site).
  • People who have a moderately to severely elevated level of a protein called albumin in their urine, measured by a specific ratio (UACR) between 500 and 5000 mg/g at screening.

Who may not be able to join:

  • People who have kidney disease that is not caused by their diabetes.
  • People whose kidney disease required treatment with strong immune-suppressing medications, or who have previously had dialysis or a kidney transplant.
  • People whose overall health is considered unstable by the doctor running the trial.
  • People who have been admitted to hospital for more than 24 hours within the 30 days before their screening visit.

Important: This trial has additional eligibility criteria not listed here. Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Clinical Trial Management, Regeneron Pharmaceuticals

Phone: 844-734-6643

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Regeneron Pharmaceuticals
Registry
ClinicalTrials.gov
Start date
9 January 2026
Est. completion
24 September 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Percent change in Urine Albumin to Creatinine Ratio (UACR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov